Amit Saxena1, Peter M Izmirly2, Sung Won Han3, Paraskevi Briassouli2, Tania L Rivera4, Hua Zhong3, Deborah M Friedman5, Robert M Clancy2, Jill P Buyon2. 1. Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, New York. Electronic address: Amit.Saxena@nyumc.org. 2. Division of Rheumatology, Department of Medicine, New York University School of Medicine, New York, New York. 3. Department of Population Health, New York University School of Medicine, New York, New York. 4. Division of Rheumatology, Department of Medicine, Scripps Memorial Hospital, La Jolla, San Diego, California. 5. Division of Pediatric Cardiology, New York Medical College, Valhalla, New York.
Abstract
BACKGROUND: Cardiac manifestations of neonatal lupus (cardiac NL) include congenital heart block and cardiomyopathy. Several candidate biomarkers were evaluated in cases at risk for cardiac NL on the basis of potential roles in inflammation, fibrosis, and cardiac dysfunction: C-reactive protein (CRP); NT-pro-B-type natriuretic peptide (NT-proBNP); troponin I; matrix metalloproteinase (MMP)-2; urokinase plasminogen activator (uPA); urokinase plasminogen activator receptor (uPAR); plasminogen; and vitamin D. OBJECTIVES: Identification of maternal and fetal biomarkers associated with development and morbidity of cardiac NL should provide clues to pathogenesis with translational implications for management. METHODS: Cord (139) and maternal (135) blood samples collected during pregnancies at risk for cardiac NL were available for study. Levels of cord and maternal CRP, cord NT-proBNP, and cord troponin I were evaluated using multiplex assays. Cord and maternal vitamin D were assessed by liquid chromatography-mass spectrometry. MMP-2, uPA, uPAR, and plasminogen were evaluated using ELISA. RESULTS: Cord CRP, NT-proBNP, MMP-2, uPA, uPAR, and plasminogen levels were higher in cardiac NL-affected fetuses than in unaffected cases, independent of maternal rheumatic disease, season at highest risk of cardiac NL development, and medications taken during pregnancy. These biomarkers were positively associated with a disease severity score derived from known risk factors for mortality in cardiac NL. Maternal CRP and cord troponin I levels did not differ between the groups. Cord and maternal vitamin D levels were not significantly associated with cardiac NL, but average maternal vitamin D level during pregnancy was positively associated with longer time to postnatal pacemaker placement. CONCLUSIONS: These data support the association of fetal reactive inflammatory and fibrotic components with development and morbidity of cardiac NL. Following CRP and NT-proBNP levels after birth can potentially monitor severity and progression of cardiac NL. MMP-2 and the uPA/uPAR/plasminogen cascade provide therapeutic targets to decrease fibrosis. Although decreased vitamin D did not confer increased risk, given the positive influence on postnatal outcomes, maternal levels should be optimized.
BACKGROUND: Cardiac manifestations of neonatal lupus (cardiac NL) include congenital heart block and cardiomyopathy. Several candidate biomarkers were evaluated in cases at risk for cardiac NL on the basis of potential roles in inflammation, fibrosis, and cardiac dysfunction: C-reactive protein (CRP); NT-pro-B-type natriuretic peptide (NT-proBNP); troponin I; matrix metalloproteinase (MMP)-2; urokinase plasminogen activator (uPA); urokinase plasminogen activator receptor (uPAR); plasminogen; and vitamin D. OBJECTIVES: Identification of maternal and fetal biomarkers associated with development and morbidity of cardiac NL should provide clues to pathogenesis with translational implications for management. METHODS: Cord (139) and maternal (135) blood samples collected during pregnancies at risk for cardiac NL were available for study. Levels of cord and maternal CRP, cord NT-proBNP, and cord troponin I were evaluated using multiplex assays. Cord and maternal vitamin D were assessed by liquid chromatography-mass spectrometry. MMP-2, uPA, uPAR, and plasminogen were evaluated using ELISA. RESULTS: Cord CRP, NT-proBNP, MMP-2, uPA, uPAR, and plasminogen levels were higher in cardiac NL-affected fetuses than in unaffected cases, independent of maternal rheumatic disease, season at highest risk of cardiac NL development, and medications taken during pregnancy. These biomarkers were positively associated with a disease severity score derived from known risk factors for mortality in cardiac NL. Maternal CRP and cord troponin I levels did not differ between the groups. Cord and maternal vitamin D levels were not significantly associated with cardiac NL, but average maternal vitamin D level during pregnancy was positively associated with longer time to postnatal pacemaker placement. CONCLUSIONS: These data support the association of fetal reactive inflammatory and fibrotic components with development and morbidity of cardiac NL. Following CRP and NT-proBNP levels after birth can potentially monitor severity and progression of cardiac NL. MMP-2 and the uPA/uPAR/plasminogen cascade provide therapeutic targets to decrease fibrosis. Although decreased vitamin D did not confer increased risk, given the positive influence on postnatal outcomes, maternal levels should be optimized.
Authors: Aurélie Ambrosi; Stina Salomonsson; Håkan Eliasson; Elisabeth Zeffer; Amanda Skog; Vijole Dzikaite; Gunnar Bergman; Eva Fernlund; Joanna Tingström; Elke Theander; Annika Rydberg; Thomas Skogh; Annika Öhman; Ulla Lundström; Mats Mellander; Ola Winqvist; Michael Fored; Anders Ekbom; Lars Alfredsson; Henrik Källberg; Tomas Olsson; Fredrik Gadler; Anders Jonzon; Ingrid Kockum; Sven-Erik Sonesson; Marie Wahren-Herlenius Journal: Ann Rheum Dis Date: 2011-09-27 Impact factor: 19.103
Authors: Carolina Llanos; Deborah M Friedman; Amit Saxena; Peter M Izmirly; Chung-E Tseng; Renata Dische; Rosanna G Abellar; Marc Halushka; Robert M Clancy; Jill P Buyon Journal: Rheumatology (Oxford) Date: 2012-02-03 Impact factor: 7.580
Authors: Pawel Zerr; Stefan Vollath; Katrin Palumbo-Zerr; Michal Tomcik; Jingang Huang; Alfiya Distler; Christian Beyer; Clara Dees; Kolja Gela; Oliver Distler; Georg Schett; Jörg H W Distler Journal: Ann Rheum Dis Date: 2014-01-21 Impact factor: 19.103
Authors: Heloisa Balan Assalin; Bruna Paola Rafacho; Priscila Portugal dos Santos; Lidiane Paula Ardisson; Meliza Goi Roscani; Fernanda Chiuso-Minicucci; Luis Fernando Barbisan; Ana Angelica Henrique Fernandes; Paula Schmidt Azevedo; Marcos Ferreira Minicucci; Leonardo Antonio Zornoff; Sergio Alberto Rupp de Paiva Journal: Circ Heart Fail Date: 2013-05-24 Impact factor: 8.790
Authors: Paraskevi Briassouli; Marc K Halushka; Joanne H Reed; Yair Molad; Karen Fox-Talbot; Lucas Buyon; Edwin Guzman; Achiau Ludomirsky; Robert M Clancy; Jill P Buyon Journal: Rheumatology (Oxford) Date: 2013-04-18 Impact factor: 7.580
Authors: Emily A McDonald; Ling Cheng; Blanca Jarilla; Marianne J Sagliba; Annaliza Gonzal; Amabelle J Amoylen; Remigio Olveda; Luz Acosta; David Baylink; Eric S White; Jennifer F Friedman; Jonathan D Kurtis Journal: Infect Immun Date: 2013-10-28 Impact factor: 3.441
Authors: Robert M Clancy; Marc Halushka; Sara E Rasmussen; Tenzin Lhakhang; Miao Chang; Jill P Buyon Journal: J Immunol Date: 2018-12-05 Impact factor: 5.422
Authors: Megan E B Clowse; Amanda M Eudy; Elizabeth Kiernan; Matthew R Williams; Bonnie Bermas; Eliza Chakravarty; Lisa R Sammaritano; Christina D Chambers; Jill Buyon Journal: Rheumatology (Oxford) Date: 2018-07-01 Impact factor: 7.580
Authors: Robert M Clancy; Androo J Markham; Tanisha Jackson; Sara E Rasmussen; Miroslav Blumenberg; Jill P Buyon Journal: Am J Physiol Heart Circ Physiol Date: 2017-06-16 Impact factor: 4.733